4.4 Article

Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Article Medicine, General & Internal

A Controlled Trial of Erenumab for Episodic Migraine

Peter J. Goadsby et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Review Clinical Neurology

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?

Amy R. Tso et al.

CURRENT TREATMENT OPTIONS IN NEUROLOGY (2017)

Review Clinical Neurology

Pharmacokinetic Variability of Drugs Used for Prophylactic Treatment of Migraine

Peer Tfelt-Hansen et al.

CNS DRUGS (2017)

Article Pharmacology & Pharmacy

Pharmacologic Characterization of AMG 334, a Potent and Selective Human Monoclonal Antibody against the Calcitonin Gene-Related Peptide Receptor

Licheng Shi et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)

Review Physiology

CALCITONIN GENE-RELATED PEPTIDE: PHYSIOLOGY AND PATHOPHYSIOLOGY

F. A. Russell et al.

PHYSIOLOGICAL REVIEWS (2014)

Review Clinical Neurology

Current practice and future directions in the prevention and acute management of migraine

Peter J. Goadsby et al.

LANCET NEUROLOGY (2010)

Article Clinical Neurology

The importance of placebo in headache research

H-C Diener et al.

CEPHALALGIA (2008)

Article Clinical Neurology

Migraine prevalence, disease burden, and the need for preventive therapy

R. B. Lipton et al.

NEUROLOGY (2007)